2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Radiation Therapy, Workforce, Adverse Events, Artificial Intelligence (AI), Generative AI, Natural Language Processing, Biological Processes, Immune Mechanism, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Systems-Based Hematology, Diseases, Infectious Diseases, Viral, Bacterial, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, CLL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

2708 Quality of life trajectories and feasibility of electronic patient-reported outcomes (ePRO) collection in adult and pediatric nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL): A prospective multicenter study

Ajay Major, MD, MBA, Ying Zheng, MS2, Yiwang Zhou, PhD3, Jessi Rogers Blake, BSN, RN, CCRP4, Nazneen Shaikh, MBBS, MPH5, Matthew Rees, MD6, Christopher Forlenza, MD7, Angela M Feraco, MD, MMSc8, Burton Appel, MD, MBA9, Monica Palese, MPH10, Michael S Binkley, MD, MS11, Jamie E Flerlage, MD, MS12, Valerie McLaughlin Crabtree, PhD13, Anna Jones, PhD14
1 University of Colorado School of Medicine, Aurora, Colorado, United States
2 St. Jude Children’s Research Hospital, Memphis, Tennessee, United States
3 St. Jude Children’s Research Hospital, Memphis, Tennessee, United States
4 St. Jude Children’s Research Hospital, Memphis, Tennessee, United States
5 St. Jude Children’s Research Hospital, Memphis, Tennessee, United States
6 St. Jude Children’s Research Hospital, Memphis, Tennessee, United States
7 Memorial Sloan Kettering Cancer Center, New York, New York, United States
8 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
9 Hackensack University Medical Center, Hackensack, New Jersey, United States
10 University of Rochester Medical Center, Rochester, New York, United States
11 Stanford University, Palo Alto, California, United States
12 University of Rochester Medical Center, Rochester, New York, United States
13 St. Jude Children’s Research Hospital, Memphis, Tennessee, United States
14 St. Jude Children’s Research Hospital, Memphis, Tennessee, United States

Background

Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is an uncommon indolent lymphoma which affects children and adults and is managed as a chronic disease given its propensity for frequent relapse during long-term survivorship. There are no prospective patient-reported outcomes (PRO) data describing health-related quality of life (HRQoL) in NLPHL, which are needed to guide shared decision-making between treatment modalities. NLPHLPRO is a multicenter pilot study evaluating the feasibility of longitudinal ePRO collection and HRQoL trajectories in adult and pediatric patients with NLPHL [NCT06098430].

Methods

Patients ≥8 years with a diagnosis of NLPHL were eligible regardless of disease status or treatment history. ePROs were administered via email from a central REDCap at baseline enrollment and at 3, 6, 9, and 12 months. Age ≥16 years completed PROMIS-29 and EORTC QLQ-C30; age 8-15 years completed PROMIS Pediatric-49 and their proxy completed parent-proxy PROMIS instruments. Adult and pediatric self-report on PROMIS measures were combined for this analysis. Feasibility targets were ≥80% baseline ePRO completion, ≥60% aggregate completion at each follow-up timepoint, and ≥50% item completion among responders. PROMIS and EORTC scores were compared with population norms using linear mixed-effects models. Predefined between-group comparisons used models adjusted for timepoint without subgroup-by-timepoint interactions.

Results

Among 53 screened patients, 30 were enrolled from 5 cancer centers: 24 ≥16 years and six 8-15 years. Common reasons for screen failure were no response/unreachable and competing life priorities. Median age was 40 years (range, 10-81); 21 (70%) were male. Most had stage I-II disease at diagnosis (67%) and few had B symptoms (13%). At baseline enrollment, 87.5% had received prior treatment, 62.5% were in remission, 12.5% were on active surveillance, and 37.5% had active disease.

Baseline ePRO completion was 87%, aggregate completion across timepoints was 68%, and item completion was 98% among responders. Aggregate ePRO completion was 72% among ages ≥16, 54% among ages 8-15, and 58% among parent proxies. Odds of ePRO completion were lower at 6 months (OR 0.13, 95% CI 0.03-0.55; P=.007) and 9 months (OR 0.21, 95% CI 0.05-0.91; P=.038), but was not associated with age group, disease or treatment status, or baseline PROMIS scores.

PROMIS scores in the overall cohort showed similar symptom burden and HRQoL as population norms: anxiety did not differ significantly at any timepoint; depression was significantly lower at baseline and 3, 9, and 12 months; pain interference was significantly lower at all timepoints; fatigue was significantly lower at 9 and 12 months; and peer/social functioning was higher at baseline and 12 months. Adult EORTC QLQ-C30 symptom scores were similar to or lower than population norms, with lower appetite loss, constipation, dyspnea, insomnia, nausea/vomiting, and pain at most timepoints.

In between-group models, active disease versus remission was not associated with significant PROMIS or EORTC differences. Compared with treated patients, active surveillance was associated with higher PROMIS depression (Δ11.1; P=.015) and sleep disturbance (Δ10.0; P<.001), and higher EORTC insomnia, worry, night sweats, and weight concerns (all P≤0.01). Patients ≤2 years from diagnosis had higher EORTC insomnia, night sweats, and weight concerns than those >2 years from diagnosis (all P<.05), without significant PROMIS differences.

Conclusions

In this prespecified interim NLPHLPRO analysis, longitudinal ePRO collection from multiple centers via centralized electronic data capture was feasible, meeting aggregate targets across follow-up timepoints with excellent item completion. Pediatric self-report and parent-proxy completion were lower, identifying opportunities to improve ePRO implementation. Screen failure was common, which may limit generalizability. HRQoL analyses did not demonstrate worse anxiety, fatigue, or symptom burden compared with population norms. Further, PROMIS and EORTC instruments can capture meaningful between-group HRQoL differences in a broad NLPHL cohort, with active surveillance and more recent diagnosis associated with higher symptom or worry burden. Ongoing accrual and follow-up in NLPHLPRO will refine longitudinal HRQoL trajectories and inform PRO endpoint selection for future NLPHL trials via the GLOW Consortium to enable comparisons among treatment paradigms.

Ajay Major, MD, MBA: GSK - Research Funding; Incyte - Research Funding; Kite - Consultancy (Includes expert testimony); Pharmacosmos - Consultancy (Includes expert testimony); Genentech - Consultancy (Includes expert testimony); BMS - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony)